Abstract
This study was carried out to test the hypothesis that the hepatic safety profile of prolonged high-dose oral naltrexone (150 mg/d) is acceptable if over-the-counter analgesic use is restricted. Data from 41 consecutive outpatients with impulse-control disorder receiving naltrexone therapy were analyzed. The mean treatment duration was 328 days and the mean naltrexone dose was 142 mg/d. Pretherapy/posttherapy mean aspartate transaminase and alanine transaminase levels in the naltrexone-alone group were 21.79/22.54 and 21.74/21.49 U, respectively (all within reference range). Although limited in scope, these findings support the hypothesis that long-term use of high-dose oral naltrexone is safe in otherwise healthy patients with impulse-control disorders who restrict their intake of acetaminophen, aspirin, or nonaspirin nonsteroidal anti-inflammatory drugs (NSAID). However, confirming studies are needed.
References
Jan 1, 1987·Biological Psychiatry·J E MitchellD Pfohl
Sep 1, 1994·Journal of Clinical Pharmacology·D S SaxA Kim
May 30, 2001·Biological Psychiatry·S W KimY C Shin
Sep 13, 2001·International Clinical Psychopharmacology·S W Kim, J E Grant
Jan 5, 2002·Journal of Clinical Psychopharmacology·S W KimR P Remmel
May 10, 2002·The Journal of Clinical Psychiatry·Jon E Grant, Suck Won Kim
May 14, 2004·Addiction·Carmen L MassonSharon M Hall
Jun 19, 2004·Addiction Biology·Colin Brewer, Voi Shim Wong
Citations
Feb 16, 2010·Journal of Addictive Diseases·Einat PelesMiriam Adelson
Jan 25, 2007·Primary Care Companion to the Journal of Clinical Psychiatry·Pinhas N DannonMoshe Kotler
Jan 23, 2016·Expert Opinion on Pharmacotherapy·Marcelo Piquet-Pessôa, Leonardo F Fontenelle
Sep 15, 2007·Clinical Pharmacokinetics·Mellar Davis
Feb 5, 2008·Alcoholism, Clinical and Experimental Research·Michael R LuceyCharles P O'Brien
Apr 17, 2012·International Journal of Endocrinology·Mehmet GunduzMesut Ozkaya
Mar 30, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Julia M A SinclairDavid S Baldwin
Dec 22, 2006·Expert Review of Neurotherapeutics·Katherine LowengrubPinhas N Dannon
Jan 29, 2011·Annals of the New York Academy of Sciences·David R Gastfriend
Mar 26, 2011·Human Psychopharmacology·Gihyun YoonJoseph Westermeyer
Aug 26, 2014·Pharmacological Reports : PR·Krzysztof ŁabuzekBogusław Okopień
Jan 16, 2008·CNS Drugs·Iulian IancuPinhas N Dannon
Jul 30, 2011·Alcoholism, Clinical and Experimental Research·Jeanette M TetraultUNKNOWN Veterans Aging Cohort Study Team
Apr 6, 2016·Clinical Neuropharmacology·Gihyun YoonJoseph Westermeyer
Oct 18, 2007·Expert Review of Neurotherapeutics·Paolo MannelliAshwin A Patkar
May 21, 2021·Journal of Diabetes·Anand SrinivasanDebasish Hota
Sep 23, 2021·Addiction·Sandra A Springer